Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Halts MOBILIZE Phase 3 Study of Riliprubart | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Sanofi Halts MOBILIZE Phase 3 Study of Riliprubart

An interim analysis by an independent data monitoring committee determined that the MOBILIZE study is unlikely to provide sufficient efficacy.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Sanofi has discontinued its riliprubart MOBILIZE phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) following an interim analysis by an independent data monitoring committee, which determined that the study is “unlikely to provide sufficient efficacy.”

No safety signals related to riliprubart were identified as part of this interim analysis. The continuation of other ongoing studies with riliprubart, including the VITALIZE phase 3 study in IVIg-treated patients with CIDP, will be evaluated accordingly.

Sanofi says it will work closely with investigators and site teams to ensure a wind-down of the MOBILIZE study, with appropriate transition of care for all enrolled patients. The company will also conduct a thorough analysis of the MOBILIZE data to inform future research directions and contribute to the broader scientific understanding of CIDP.

More Sanofi News

Sanofi recently announced a new agreement with Owkin, an agentic AI company pioneering biological artificial superintelligence for drug discovery and development.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics